ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Radiotherapy for Merkel cell carcinoma: recommendations from the DEGRO Dermatooncology Working Group.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare malignancy with an annual incidence in Germany of 5.2 per million for men and 3.8 per million for women, predominantly affecting sun-exposed areas in older adults. Despite a frequently unfavorable prognosis, outcomes are multifactorial and depend on tumor site, disease stage, performance status, patient age, sex, and immune competence. The current standard of care prescribes surgical resection followed by adjuvant radiotherapy of the tumor bed, ideally initiated within 8 weeks after surgery to optimize clinical outcomes. In case of lymph node involvement, lymph node dissection and/or radiotherapy of the involved nodal basin are recommended. Furthermore, new evidence supports the effectiveness of shorter radiotherapy approaches, with moderate hypofractionated or even ultrahypofractionated schedules serving as effective options for certain patients, particularly those with frailty or comorbidities, or when it is clinically necessary to minimize the treatment burden. In cases of inoperability, refusal of surgery, or significant frailty, definitive local radiotherapy can achieve sufficient disease control. The synergistic potential of combining immunotherapy with radiation in advanced cases remains a key area for ongoing research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.